Document Detail

Favourable response to therapy with the anti-CD20 monoclonal antibody rituximab in primary chronic cold agglutinin disease.
MedLine Citation:
PMID:  11722415     Owner:  NLM     Status:  MEDLINE    
The 'primary' form of chronic cold agglutinin disease is a clonal B-cell lymphoproliferative disorder that is notoriously difficult to treat with drugs, including corticosteroids, alkylating agents, alpha-interferon and purine analogues. We performed a small, open, uncontrolled, prospective study to evaluate the effect of therapy with the monoclonal anti-CD20 antibody rituximab. Six patients with clonal CD20(+)kappa(+) B-cell proliferation received seven courses of rituximab 375 mg/m(2), d 1, 8, 15, and 22. One patient achieved a complete response. Four partial responses were observed, including a response to re-treatment in one patient. Two patients were categorized as non-responders. Haemoglobin levels increased by a median of 4.1 g/dl in the total group and 4.7 g/dl in the responders, who also experienced a substantial improvement of clinical symptoms. The treatment was well tolerated. We discuss the effect of rituximab therapy compared with other treatment options, and try to explain why two individual patients did not respond. Despite the small numbers, the results are very encouraging. Further studies of rituximab therapy for chronic cold agglutinin disease are warranted.
S Berentsen; G E Tjønnfjord; R Brudevold; B T Gjertsen; R Langholm; E Løkkevik; J H Sørbø; E Ulvestad
Related Documents :
20345885 - Second-line treatment in the malawi antiretroviral programme: high early mortality, but...
2989515 - Human fibroblast interferon in cervical and vulvar intraepithelial neoplasia associated...
19838125 - Prior therapy influences the efficacy of lamivudine monotherapy in patients with lamivu...
12226815 - Virological and immunological effects of salvage therapy following treatment interrupti...
23634305 - Gross hematuria in patients with prostate cancer: etiology and management.
23014355 - Presumed hydrogen sulfide-mediated neurotoxicity after streptococcus anginosus group me...
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  British journal of haematology     Volume:  115     ISSN:  0007-1048     ISO Abbreviation:  Br. J. Haematol.     Publication Date:  2001 Oct 
Date Detail:
Created Date:  2001-11-27     Completed Date:  2001-12-19     Revised Date:  2004-11-17    
Medline Journal Info:
Nlm Unique ID:  0372544     Medline TA:  Br J Haematol     Country:  England    
Other Details:
Languages:  eng     Pagination:  79-83     Citation Subset:  IM    
Department of Medicine, Haugesund County Hospital, Haugesund, Norway.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Aged, 80 and over
Anemia, Hemolytic, Autoimmune / blood,  drug therapy*,  immunology
Antibodies, Monoclonal / therapeutic use*
Antigens, CD20 / immunology*
B-Lymphocytes / immunology
Bone Marrow Cells / immunology
Chronic Disease
Hemoglobins / metabolism
Immunoglobulin M / blood
Middle Aged
Prospective Studies
Treatment Outcome
Reg. No./Substance:
0/Antibodies, Monoclonal; 0/Antigens, CD20; 0/Hemoglobins; 0/Immunoglobulin M; 0/rituximab
Comment In:
Br J Haematol. 2002 Jun;117(4):998-9   [PMID:  12060148 ]

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Hb H hydrops foetalis syndrome: a case report and review of literature.
Next Document:  The ratio of serum transferrin receptor and serum ferritin in the diagnosis of iron status.